Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen

AIDS

Volumn 22, Issue 17, 2008, Pages 2279-2289

  Fox, Zoe ^a,b   Phillips, Andrew ^b   Cohen, Cal ^c   Neuhaus, Jacquie ^d   Baxter, John ^e   Emery, Sean ^f   Hirschel, Bernard ^g   Hullsiek, Kathy Huppler ^d   Stephan, Christoph ^h   Lundgren, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Department of Anesthesiology   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Genotypic resistance emergence; Non nucleoside reverse transcriptase inhibitor based therapy; Treatment interruption strategies; Viral resuppression

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RACE; STATISTICAL ANALYSIS; TREATMENT INTERRUPTION; TREATMENT WITHDRAWAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS SUPPRESSION;

ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 56549110656     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328311d16f     Document Type: Article

References (23)

1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
2. Arduino R. CD4 cell count-guided treatment interruption: be smart and wait for more evidence. Clin Infect Dis 2005; 40:735-737.
3. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Antihuman immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617.
4. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson CR, Gulick RM, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-407.
5. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretroviral therapy. AIDS 2007; 21:1673-1682.
6. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16:2342-2344.
7. Dargere S, Parienti JJ, Verdon R. Treatment resistance after sequential interruption of a nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS 2007; 21:879-880.
8. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
9. US Department of Health and Human Services. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Clinical Guidelines Portal; 2007.
10. Hawkins D, Blott M, Clayden P, de Ruiter A, Foster G, Gilling-Smith C, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med 2005; 6:107-148.
11. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping nonnucleoside therapy. AIDS 2006; 20:701-710.
12. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
13. Daniel N, Schneider V, Pialoux G, Krivine A, Grabar S, Nguyen TH, et al. Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. AIDS 2003; 17:2126-2129.
14. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado J, Frost S, Petropoulos CJ, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-899.
15. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-1443.
16. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21:169-178.
17. 3 at first interruption: final results of the TRIVACAN Trial. 15th Conference on Retroviruses and Opportunistic Infections 2008; Session 127:778.
18. Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, et al. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 2007; 46:39-47.
19. Darwich L, Bellido R, Blanco A, Ruiz L, Esteva A, Cabrera C, et al. Nonnucleoside reverse transcriptase inhibitor (NNRTI) plasma concentrations determine different NNRTI resistance pattern in virological responders during treatment interruptions [abstract number 64]. Antivir Ther 2007; 12(S73).
20. Arnedo-Valero M, Garcia F, Gil C, Cuila T, Fumero E, Castro P, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41:883-890.
21. Metzner KJ, Allers K, Rauch P, Harrer T. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 2007; 21:703-711.
22. Simen BB, Huppler Hullsiek K, Novak RM, MacArthur RD, Baxter JD, Huang C, et al. Prevalence of low abundant drug resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral naive patients and the impact on virologic outcomes [abstract number 134]. Antivir Ther 2007; 12(S149).
23. Hare CB, Mellors J, Krambrink A, Su Z, et al. Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421-424.